Cosentyx (secukinumab) prior authorization
UnitedHealthcare prior authorization/notification policy for Cosentyx (secukinumab) prefilled syringe or Sensoready pen, defining initial and reauthorization clinical criteria for multiple labeled indications and program operational notes. Effective for the payer's commercial utilization management processes.
1/2026 annual review updated 'not used in combination' verbiage and examples with no change to clinical intent.
1/2024 added coverage criteria for new indication for Hidradenitis Suppurativa (HS).
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.